NEW YORK (GenomeWeb News) — Merck has closed its $1.1-billion cash acquisition of Sirna Therapeutics, Merck said last week.
 
Merck originally announced its plan to acquire the RNAi company on Oct. 30, 2006, but waited for regulatory approval and for Sirna shareholders to give the nod, which they did on Dec. 28, 2006.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.